Replies to post #403819 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Dude, that’s marketing effectively for them but also for Sawston, which belongs to NWBO. As I mentioned in my other post, it effectively functions, as a facility, like an incubator for Advent and for the bios they may ultimately recruit once they finish building it FOR NWBO. NWBO owns it, it’s a cost to fully staff it and keep it ready for commercial production until they are both approved for commercial sales and have the demand to use all of the space, which all needs to be maintained. Initially NWBO will only be doing compassionate use/ out of pocket sales, and that will be likely to be relatively low volume, when compared to commercial sales upon approval that will be covered. So symbiotically, Advent is the facilities manager and can use the unused space during that time to build their business and to help other small bios as their contract manufacturer. The contract arrangements allow them to make proposals for work to NWBO and subject to NWBO’s approval, different projects can commence. Presumably it will entail revenue streams for both companies. Not likely a lot for NWBO since it is providing mainly space and Advent has to be competitive, but it creates a local facility and does not require that NWBO have all of the costs of maintaining the entire space, and all the employees, until approval. That can be a huge cost up front.

Basically it is bootstraps for everyone including NWBO. Everyone is operating at maximal entrepreneurial efficiency, to the best extent possible.

[MI Dendream]

Anders, I am trying to understand where you want to go with this, aka, what are your motivations?

Another Cognate in the making, financed by NWBO shareholders

The Cognate situation left a bad taste in most everyone’s mouth whether or not legal, not only because of the inherent conflict of interest, but also because of the enormous capital expenditure by NWBO on a facility owned by Cognate at a time when those finances may have been better spent internally. In this situation, the expenses have been substantially less and the facility and equipment are owned by NWBO. There is no question Advent and NWBO are currently bound together by contracts and opportunity, but NWBO owns the IP, will own the license to market, owns the facility and the process. The facility itself must be cGMP certified for the production of cell therapy. While Advent may hold the license to operate the facility in the production of DCVax they cannot do so without permission from NWBO. Without details of the contract, we don’t know the out clause, but NWBO could hire another operator to gain production license in the facility at some point in the future or hire their own employees and do it themselves. The cGMP certification will need to be renewed regardless of who the operator is. Advent could build their own facility, but would need to license that facility and production within and could not produce DCVax without NWBO permission. The license doesn’t transfer to a new facility, it would need to be certified as well. From the statements I have read, it appears that if any sub-contract manufacturing occurs in the facility under Advent, NWBO will benefit financially from that contract. I could be wrong about this but that is my impression. I don’t know the details of the relationship, but it doesn’t look fishy to me at bird’s eyes view.

This situation is very different than Cognate. So, I ask again, what is it you are trying to accomplish because it appears as though you are spinning unnecessary doubt?

You are an attorney. If you think the situation is illegal or not in the best interest of shareholders, then do something about that. I personally don’t think you have a case, but I am not an attorney so that viewpoint is uneducated and irrelevant.